NEW YORK, June 19, 2017 /PRNewswire/ --
Ahead of today's trading session, DailyStockTracker.com concentrates on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. This industry includes the manufacturing and marketing of drugs as a result of direct research and development. Equities under review are: Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), Cytori Therapeutics Inc. (NASDAQ: CYTX), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), and Moleculin Biotech Inc. (NASDAQ: MBRX). Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at:
Last Friday, Berkeley Heights, New Jersey headquartered Cyclacel Pharmaceuticals Inc.'s stock jumped 5.15%, to close the day at $4.29. A total volume of 27,545 shares was traded. The Company's shares have advanced 11.43% in the previous three months. The stock is trading 10.50% below its 200-day moving average. Additionally, shares of Cyclacel Pharma, which focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases, have a Relative Strength Index (RSI) of 42.42. The free research report on CYCC is available at:
Shares in San Diego, California headquartered Cytori Therapeutics Inc. saw a decline of 3.92%, finishing Friday's session at $0.98. The stock recorded a trading volume of 401,332 shares. The Company's shares have gained 2.08% in the last month. The stock is trading below its 50-day moving average by 7.54%. Furthermore, shares of Cytori Therapeutics, which develops cellular therapeutics for specific diseases and medical conditions, have an RSI of 44.01.
On June 01st, 2017, Cytori Therapeutics announced plans to introduce its next-generation Celution® technology. The technology incorporates new hardware and enhanced software that substantially improve performance and maintain compliance with evolving global medical device and cell therapy standards. It is available for pre-orders, with first product shipments anticipated to begin in the third quarter of 2017. The complimentary report on CYTX can be downloaded at:
La Jolla Pharma
San Diego, California headquartered La Jolla Pharmaceutical Co.'s stock finished 1.63% lower at $26.56 last Friday at the close. A total volume of 2.24 million shares was traded, which was higher than their three months average volume of 568,440 shares. The Company's shares have advanced 51.51% on an YTD basis. The stock is trading above its 200-day moving average by 11.29%. Additionally, shares of La Jolla Pharma, which focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases, have an RSI of 37.24. Visit us today and download our complete research report on LJPC for free at:
Houston, Texas headquartered Moleculin Biotech Inc.'s shares ended the session 5.19% higher at $0.81. The stock recorded a trading volume of 275,546 shares. Shares of the Company have advanced 10.20% in the last month. The stock is trading 2.67% below its 50-day moving average. Moreover, shares of Moleculin Biotech, which focuses on the development of anti-cancer drug candidates, have an RSI of 50.25.
On June 15th, 2017, Moleculin Biotech announced that the Company has asked its contract research organization, Theradex Systems, Inc., to expand its engagement to include clinical sites in Poland for its planned Phase-I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia. By expanding its engagement with Theradex, the Company helps ensure tight coordination of clinical activity between the US and Poland. Get free access to your technical report on MBRX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA